Vasopeptidase inhibitors: will they have a role in clinical practice? - Wikidata - wikimedia - TriplyDB

Vasopeptidase inhibitors: will they have a role in clinical practice?

Vasopeptidase inhibitors: will they have a role in clinical practice?

http://www.wikidata.org/entity/Q35608907

about

Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease.Atrial natriuretic peptide and related peptides.An update on hybrid drugs in cardiovascular drug research.Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.Flow cytometric technique for determination of prostasomal quantity, size and expression of CD10, CD13, CD26 and CD59 in human seminal plasma.

P2860

Q27667064-8C3B8799-79D9-4443-A55D-12A5419168F3 Q33496583-DA1D7418-D00F-4C85-9970-1D6B65B90839 Q36896608-7B8D3032-5028-41DB-B78B-D790C4C3C83F Q38090661-1B4C42F1-3719-4C1B-B52A-48DDDD4533D6 Q38817943-62CBC547-BDDB-452C-A172-EA89D1158CF9 Q46988045-8E49BF60-1D83-413C-89B5-5CC46A908F4F

P2860

Vasopeptidase inhibitors: will they have a role in clinical practice?

http://www.wikidata.org/entity/Q35608907

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Vasopeptidase inhibitors: will they have a role in clinical practice?

@ast

Vasopeptidase inhibitors: will they have a role in clinical practice?

@en

type

label

Vasopeptidase inhibitors: will they have a role in clinical practice?

@ast

Vasopeptidase inhibitors: will they have a role in clinical practice?

@en

prefLabel

Vasopeptidase inhibitors: will they have a role in clinical practice?

@ast

Vasopeptidase inhibitors: will they have a role in clinical practice?

@en

P1433

Q35608907-A56470CE-2340-4DDC-A5DD-531BBBB37B3D

P1476

Q35608907-5FBD2A41-C229-4780-B4C1-0D8D91A8FAB4

P2093

Q35608907-31E9AD16-0802-49A8-8306-1D489B7D78EB

Q35608907-7BA32236-B622-4E4B-A357-689474E54CF4

Q35608907-C19A4695-BF73-493E-B4ED-E77E4272E470

P2860

Q35608907-03BBFA1A-BE9C-45BA-9F01-842A9CE07003

Q35608907-0E9ED068-63FE-414D-8150-71EBBC1C6D42

Q35608907-0EAA23D5-43C6-4E54-9976-FACBBFA299AC

Q35608907-14FBD4D1-9EEB-477F-8404-9218FF1AF64E

Q35608907-1928A98E-1FEB-4F7D-9700-D25F1FFB753F

Q35608907-1DCD3AFA-B872-4BF9-8B7E-5DD18C7A6B0B

Q35608907-1F4CF48C-93B7-407F-82FE-6161E0E72F9C

Q35608907-1F9058AE-1007-4505-9A82-5C6680AC0A3B

Q35608907-2202F9D8-162F-49B9-95A3-6FE83F1D6C75

Q35608907-2A901AB4-795C-412F-BC91-104992ECCCCD

P304

Q35608907-BF573F11-15D1-485B-AEFD-C8B5597E17EE

P31

Q35608907-81976323-947E-4F1A-A25A-DD712A6449AA

Q35608907-fc5e09e5-eb0a-4534-9e1c-661491b75d55

P356

Q35608907-6BBE7F59-7EF3-4FE2-9D91-6A104D4B912A

P407

Q35608907-BE558EBE-5A92-4BB4-9EEF-054D45ED0CD2

P433

Q35608907-EE08412D-9B40-4720-9CC4-5A50C39BE621

P478

Q35608907-34808364-2884-4CBF-90FB-8AA739572121

P577

Q35608907-E7244C27-4861-487B-A8B0-253394F33197

P5875

Q35608907-7D83F74A-A045-495C-8027-BF848088A0E0

P698

Q35608907-8525D9B9-0AA9-4735-A4F6-1D6A9E81CF08

P932

Q35608907-EA7BAFF9-0D64-4D17-B81F-435B46DBD5FE

P356

J.1365-2125.2003.01947.X

P1433

British Journal of Clinical Pharmacology

P1476

Vasopeptidase inhibitors: will they have a role in clinical practice?

@en

P2093

Matthew I Worthley

http://www.w3.org/2001/XMLSchema#string

Roberto Corti

http://www.w3.org/2001/XMLSchema#string

Stephen G Worthley

http://www.w3.org/2001/XMLSchema#string

P2860

Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase

Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11

GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico

Molecular cloning and chromosomal assignment of the mouse C-type natriuretic peptide (CNP) gene (Nppc): comparison with the human CNP gene (NPPC)

Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Neuroendocrine activity in untreated heart failure

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat.

Two cardiac natriuretic peptide genes (atrial natriuretic peptide and brain natriuretic peptide) are organized in tandem in the mouse and human genomes.

P304

27-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2125.2003.01947.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8957638

http://www.w3.org/2001/XMLSchema#string

P698

14678337

http://www.w3.org/2001/XMLSchema#string

P932

1884420

http://www.w3.org/2001/XMLSchema#string